LAS VEGAS — (05-21-20) — The HIV Prevention Trial Network announced on Monday a breakthrough in HIV Prevention, Injectable PrEP. This is huge news not only for the LGBTQ community but also for the gay adult film industry.
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP).
The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men. With the announcement by the HIV Prevention Trial Network on their breakthrough Injectable PreP, heads turned throughout the AIDS Research community.
After the announce during a press conference held on May 18 by the HIV Prevention Trial Network, AIDS Healthcare Foundation announced their support for the study and fo PrEP.
“From the very beginning of this debate, AHF voiced significant concerns about PrEP’s reliance on patient adherence to a daily pill regimen to achieve its preventive benefit,” said Michael Weinstein, president of AHF. “ViiV’s remarkable study results here validate many of our earlier criticisms and concerns about PrEP. Cabotegravir looks to be an exciting new addition to the world of HIV prevention.” said Weinstein.
Watch HPTN 083 Study Update Press Briefing May 18 2020
No word yet as to when cabotegravir will be available in the United States but as soon as it is approved, we’ll bring you the details.
For more information, visit the HIV Prevention Trial Network.
Article by: Paul Goldberg, Staff Writer
Sign Up Below for #JRLCHARTS Breaking News and Follow @JRLCHARTS Daily on Twitter
- Cast Your Vote for Williams Trading University Retail Education Program of the Year 2022 - December 3, 2021
- 2EROS Launch Its ‘Down Under Summer 2022 Collection’ Commercial - December 3, 2021
- Biden Says ‘End of HIV Epidemic Is Within Reach’ on World AIDS Day - December 3, 2021